SUPPORT-E

Supporting high-quality evaluation of CCP throughout Europe

About

The SUPPORT-E project was a research project funded by the European Commission and coordinated by the European Blood Alliance, bringing together some of Europe’s major blood establishments. Its aim was to support high-quality clinical and scientific evaluation of COVID-19 convalescent plasma (CCP) and to help EU countries in both assessing the efficacy of a new therapeutic solution to deal with the SARS-CoV-2 crisis and developing new strategies to face potential future pandemics.

Project duration: 07.2020 – 12.2024

The trial

The SUPPORT-E team developed and implemented COVIC-19, a randomised trial designed to evaluate, to the highest scientific standard, the effectiveness and safety of CCP (COVID-19 Convalescent Plasma) as early treatment in immunocompromised COVID-19 patients.

The trial, which was based on a thorough SWOT analysis of tens of thousands of scientific articles, published clinical trials and monitored access programmes, enrolled 120 patients who met the following criteria: they had a confirmed COVID-19 infection, belonged to the category of vulnerable patients (such as those who are immunocompromised), did not require hospitalisation, and could start treatment within 7 days of a positive screening test.

COVIC-19 results will ultimately contribute to the overall assessment of the clinical effectiveness of CCP as part of a coordinated approach for treating new infections with pandemic potential in the future.

Results

SUPPORT-E strengthened the evidence base for COVID-19 convalescent plasma (CCP) through clinical research, support for the COVIC-19 trial, the development of a European database and work to improve the standardisation of antibody testing. These activities helped clarify the effectiveness of CCP and identify gaps requiring further research. More information can be found here.

Recommendations

The project recommends improving pandemic preparedness through coordinated expert networks, flexible funding, systematic evidence reviews and better data sharing. It also highlights the need to strengthen plasma collection capacity, harmonise antibody testing and prioritise robust clinical trials, particularly to clarify the potential benefits of CCP for vulnerable and immunocompromised patients. More information can be found here. 

Project partners

  1. European Blood Alliance – Belgium (The Netherlands in the GA)
  2. Etablissement Francais du Sang – France
  3. DRK-Blutspendedienst – Baden Wurttemberg Hessen – Germany
  4. Stichting Sanquin Bloedvoorzienning – The Netherlands
  5. Belgische Rode Kruis – Belgium
  6. Aarhus Universitetshospital – Denmark
  7. Instituto Superiore di Sanita – Italy
  8. Fondazione IRCCS Policlinico San Matteo – Italy
  9. Azienda Socio Sanitaria Teritoriale di Mantova (Asst di Mantova) – Italy
  10. NHS Blood and Transplant – UK
  11. Statens Serum Institut – Denmark
  12. Blutspende SRK Schweiz AG – Switzerland

Videos

SUPPORT-E Project Presentation
SUPPORT-E Project Report
SUPPORT-E COVIC-19 Report

Expand the map
  • 17 million donations
  • 445 million population
ES PT GR LT DK MT IT DE RO SE NO FI UA EE LV CH HU ME BIH FR GB NL RS HR SI AT AL MK IE IS BE LU